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Original Paper 
Cancer that is arising from uncontrolled cell prolif-
eration, with frequent spread of abnormal cells from 
a primary tumor site to distant sites in the body, often 
culminating in death and led to killing of millions of 
people in each year in the world (1-3). So that, diag-
nosis of approximately 12 million new cancer cases 
were expected in the worldwide in each year, which 
will increase up to 16 million by 2020 (4-6).  
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Advances in recombinant DNA technology, protein and metabolic 
engineering and in silico investigation have led to the use of cytotoxic 
products of microorganisms for anti-cancer drugs development based on 
targeting cell surface antigens of cancerous cells, which are known as 
immunotoxins. Therefore, understanding the structural and functional 
characteristics of these types of the antigens, while leading to present a new 
way for cancer diagnosis, provide us targets for immunotoxins designing. 
Considering, reported cancerous cell surface specific antigens of various 
tissues were gathered, and then corresponding nucleotide and protein 
sequences as well as 3D structures of them were derived from related 
databanks. Subsequently, several in silico programs were used for sequence, 
interaction, as well as expression characterization on normal and cancerous 
tissues. The results of this analysis lead to the disclosure cell surface specific 
antigens including PSMA, PSA, EPCAM, GPA33, EPHA3, IGFIR, AFP, 
CEA CAM 7, CEACAM5, CEA CAM3, CA15-3, NSE, HCG, MSLN, and 
MAGE4 with different expression on normal and cancerous tissues, and 27 
key matching ligands. Among these antigens, MAGE4 showed high 
expression on the cell surface of 20 different of cancer tissues. Meanwhile, 
nucleotide and protein sequence analysis of the antigens and corresponding 
ligands lead to provide a series of therapeutic targets for immunotoxins 
designing as well as for cancer diagnosis, which ought to be more tested.  
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The etiology of this devastating disease includes 
both exogenous (tobacco, infectious organisms, 
chemicals, radiation) and endogenous factors 
(inherited mutations, epigenetic changes, hormones)
(7, 8). However, cancer treatments do not have 
potent medicine as the currently available drugs and 
surgery approaches are causing side effects in some 
instances such as bleeding, hair loss, diarrhea, 
development of multidrug resistance, and 
immunosuppression (9-11). Considering new drug 
development has shifted from cytotoxic agents to 
molecularly targeted therapy, supplementing or a 
combined of conventional and modern anticancer 
therapies to achieving treatment approaches which 
should act exclusively against tumor cells; without 
side effects on the human body (1, 12). In this 
regard, a growing number of molecularly targeted 
agents such as monoclonal antibodies and 
immunotoxins approved for the treatment of 
malignancies (13-15). In this context, immunotoxins 
pipeline consists of a Food and Drug Administration 
(FDA) approved as ONTAK, as well as several in 
different phases of the clinical pipeline and a large 
number of them in the preclinical pipeline (16-
18).Immunotoxins that are smart fusion proteins of 
toxic and ligands components, targeting cancer cells 
via cell-surface specific antigens as target (19). The 
clinical development of immunotoxins suffering by a 
variety of problems such as poor antigen specificity, 
low cytotoxicity, and immunogenicity which some 
of them including improvement of tumor targeting 
considered in this study based on in silico 
investigation. 
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MATERIALS AND METHODS 
To determine the structure and function of 
cancerous cell surface specific antigens, a 
comprehensive profile of reported antigens were 
gathered. Subsequently, the nucleotide sequences 
and corresponding proteins were retrieved from 
NCBI, Uniprot, and EMBL. The expression of each 
antigen was measured by protein atlas program and 
then compared to literature data. 3D structure of 
selected antigens were retrieved or prepared via 
PDB, SWISS-MODEL and or Modeler program. 
Moreover, corresponding ligands of selected 
antigens were then determined by data survey and 
using of String program. The protein sequences of 
selected antigens and ligands were analyzed via 
Nucleotide and Protein Blast under various matrixes, 
InterProScan 5, CD Search and Motif Scan. Finally, 
the binding affinity of ligand to antigen was 
performed using HexandCluspro program and then 
visualized their interaction via Pymol software. 
Moreover, in silico expression assays were carried 
out in at least triplicate, and the generated data were 
expressed as mean _ standard deviation. One-way 
analysis of variance (ANOVA) was used to analyze 
the antigen expression on different tissues. ANOVA 
was done by a Tukey post hoc test. Statistical 
significance was considered at P < 0.05. All 
statistical analyses were carried out with SPSS 16.0  
(SPSS Inc., Chicago, IL, USA). 
 
RESULTS  
Antigen profiling led to disclosure a series of 
specific antigens with various expressions on the cell 
surface of malignant cells (table 1). As showed in 
this table, these antigens encoded from different 
genes with various characteristic. On the other hand, 
this data reveal that some of the cancerous cells 
could be expressed several antigens at different 
levels.  
Moreover, in silico expression assay of the  selected 
antigens showed different data from literature. So 
that the most of them could be expressed at least at 
different level from very low up to very high on the 
cell surface of 20 malignant tissues which are 
including Breast, Carcinoid, Cervical, Colorectal, 
Endometrial, Melanoma, Ovarian, Pancreatic, 
Prostate, Renal, Skin, Stomach, Testis, Glioma, 
Thyroid, Head and neck, Urothelial, Liver, Lung, 
Lymphoma. Nonetheless, some of these antigens 
showed expression on the surface of the normal 
cells.   
Table 1.Characteristics of some of the cancerous cell surface specific antigens 
Cell/Tissue Exon count Length (bp) Chr. Location Gene ID Gene Antigen 
lung/liver 9 17881 2 4072 EPCAM EPCAM 
Breast/
stomach 
15 19567 4 174 AFP AFP 
Colorectal/
liver 
8 7092 1 4582 MUC1 CA 15-3 
Lung/ovanan 7 37787 1 10223 GPA33 GPA33 
liver/
colorectal 
23 315484 15 3480 IGF1R IGF1R 
Breast/
cervical 
17 374611 3 2042 EPHA3 EPHA3 
Glioma/renal 12 9247 12 2026 ENO2 NSE 
liver/Ovarian 19 8101 16 10232 MSLN MSLN 
Skin/testis 8 12282 X 4103 MAGE4 MAGE4 
Prostate/liver 5 21907 19 1087 CEACAM7 CEACAM7 
Colorectal 10 21823 19 1048 CEACAM5 CEACAM5 
Breast/lung 8 14964 19 1084 CEACAM3 CEACAM3 
prostate 5 5850 19 354 KLK3 PSA 
Head & neck 20 62040 11 2346 FOLH1 PSMA 
lung 5 9650 6 1081 CGA HCG 
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Figure 1. In silico expression assays of the MAGE4 on the malignant tissues of different cancer type. Error bars indicate 
standard deviation  
Figure 2. Corresponding ligands of MAGE4 as and sample of ligands 
Anyway, among these antigens, MAGE4 showed 
high expression only on the cell surface of malignant 
tissues except on the normal cells of the testis which 
could be ignored for presence of the testis blood 
barrier (Figure 1).  
On the other hand, in silico survey for ligands 
detection of these antigens led to disclosure at least 
150 corresponding ligands with specific structure 
and functions (Figure 2). As showed in this figure at 
least 10 proteins have potency for binding to 
MAGE4 as corresponding ligands.  
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However, assessment the validity of detected 
ligands based on scoring and binding affinity (Figure 
3), led to the selection 8 proteins among 150 ligands 
which are including FLNA, SERPINA1, LHB, 
PSCA, ZBTB17, CLDN7, HLA-A, SRC with 
suitable in structure and binding affinity to the their 
antigens. As showed in the figure 4 among these 
ligands, ZBTB17 showed the highest binding 
affinity to corresponding antigen.    
Conclusion: Analysis of the nucleotide sequences of the selected antigens led to providing significant 
data for biomarker investigation (data not shown). Taken together, the results of this research provide several 
cell surface specific antigens of malignancies with corresponding ligands that could be application in cancer 
target therapy. Meanwhile a series of the sequences were gathered which could be provide material for 
biomarker investigation in cancer diagnosis and cancer prognosis. 
Figure 4. Assessment the binding affinity of the selective ligands to corresponding antigens based on interaction 
energy. Error bars indicate standard deviation. 
Figure 3. Interaction between MAGE4 and ZBTB17 in 3D structure, hydrogen bonds and corresponding involved 
amino acid in interaction between ligand and antigen showed with discontinued yellow lines 
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